Symbols / CUE Stock $0.58 -13.42% Cue Biopharma, Inc.
CUE (Stock) Chart
About
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Stock Fundamentals
Scroll to Statements| Market Cap | 56.65M | Enterprise Value | 32.62M | Income | -26.60M | Sales | 27.47M | Book/sh | 0.27 | Cash/sh | 0.29 |
| Dividend Yield | — | Payout | 0.00% | Employees | 29 | IPO | — | P/E | — | Forward P/E | -1.21 |
| PEG | — | P/S | 2.06 | P/B | 2.12 | P/C | — | EV/EBITDA | -1.28 | EV/Sales | 1.19 |
| Quick Ratio | 2.64 | Current Ratio | 2.74 | Debt/Eq | 15.88 | LT Debt/Eq | — | EPS (ttm) | -0.28 | EPS next Y | -0.48 |
| EPS Growth | — | Revenue Growth | 12.92% | Earnings | 2026-03-16 | ROA | -44.56% | ROE | -121.11% | ROIC | — |
| Gross Margin | -26.86% | Oper. Margin | 8.92% | Profit Margin | -96.85% | Shs Outstand | 97.66M | Shs Float | 97.07M | Short Float | 2.74% |
| Short Ratio | 1.15 | Short Interest | — | 52W High | 1.03 | 52W Low | 0.17 | Beta | 1.58 | Avg Volume | 9.40M |
| Volume | 10.17M | Target Price | $4.00 | Recom | Strong_buy | Prev Close | $0.67 | Price | $0.58 | Change | -13.42% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-25 | init | LUCID CAPITAL MARKETS | — → Buy | $4 |
| 2025-04-02 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $2 |
| 2024-08-20 | main | Stifel | Buy → Buy | $4 |
| 2024-07-26 | main | JMP Securities | Market Outperform → Market Outperform | $2 |
| 2024-07-26 | main | Piper Sandler | Overweight → Overweight | $3 |
| 2024-04-09 | main | Stifel | Buy → Buy | $8 |
| 2024-04-09 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2024-04-03 | reit | Piper Sandler | Overweight → Overweight | $8 |
| 2024-03-13 | init | Jefferies | — → Buy | $6 |
| 2023-11-06 | main | Piper Sandler | Overweight → Overweight | $8 |
| 2023-06-15 | reit | Stifel | Buy → Buy | $8 |
| 2023-05-15 | reit | JMP Securities | Outperform → Outperform | $15 |
| 2023-03-22 | main | Stifel | — → Buy | $8 |
| 2023-03-22 | reit | Oppenheimer | — → Outperform | $10 |
| 2022-11-21 | init | Piper Sandler | — → Overweight | $7 |
| 2022-08-24 | main | Oppenheimer | — → Outperform | $10 |
| 2022-03-21 | main | Oppenheimer | — → Outperform | $26 |
| 2022-03-18 | main | Craig-Hallum | — → Buy | $26 |
| 2020-11-24 | init | Berenberg | — → Buy | $30 |
| 2020-05-20 | main | Stifel | — → Buy | $30 |
News
RSS: Latest CUE news- Cue Biopharma cuts share count to 3.3M as it seeks Nasdaq compliance - Stock Titan Wed, 22 Apr 2026 12
- Cue Biopharma, Inc. Announces 1-for-30 Reverse Stock Split Effective April 23, 2026 - Quiver Quantitative Wed, 22 Apr 2026 12
- Cue Biopharma to implement 1-for-30 reverse stock split on Nasdaq - Investing.com Wed, 22 Apr 2026 12
- What's Behind The Drop In Cue Biopharma Stock Today? - Benzinga Wed, 22 Apr 2026 16
- Cue Biopharma Announces 1-for-30 Reverse Stock Split - TipRanks Wed, 22 Apr 2026 13
- Cue Biopharma (CUE) Appoints Lucinda Warren as Interim President and CEO - Yahoo Finance Mon, 20 Apr 2026 14
- Cue Biopharma (CUE) Stock: Is It Worth Opening a Position (-1.46%) 2026-04-18 - Trending Entry Points - Xã Thanh Hà Sat, 18 Apr 2026 23
- Cue Biopharma (CUE) Stock: Is It Worth Opening a Position (-1.46%) 2026-04-18 - High Yield Stocks - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 23
- Cue Biopharma implements 1-for-30 reverse stock split By Investing.com - Investing.com Australia hu, 23 Apr 2026 02
- Cue Biopharma (NASDAQ: CUE) sets 1-for-30 reverse split to support Nasdaq bid - Stock Titan Wed, 22 Apr 2026 12
- Cue Biopharma announces 1-for-30 reverse stock split - TipRanks Wed, 22 Apr 2026 15
- $CUE stock is down 15% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Mar 2026 07
- Top movers in Tuesday's session - ChartMill ue, 21 Apr 2026 19
- $CUE stock is up 20% today. Here's what we see in our data. - Quiver Quantitative Mon, 05 Jan 2026 08
- Cue Biopharma, Inc. Announces Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative hu, 18 Dec 2025 08
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
27.47
+195.75%
|
9.29
+69.16%
|
5.49
+340.96%
|
1.25
|
| Operating Revenue |
|
27.47
+195.75%
|
9.29
+69.16%
|
5.49
+340.96%
|
1.25
|
| Operating Expense |
|
53.99
+6.11%
|
50.88
-11.49%
|
57.48
+5.00%
|
54.75
|
| Research And Development |
|
37.74
+3.99%
|
36.30
-11.05%
|
40.80
+5.76%
|
38.58
|
| Selling General And Administration |
|
16.24
+11.37%
|
14.59
-12.56%
|
16.68
+3.16%
|
16.17
|
| General And Administrative Expense |
|
16.24
+11.37%
|
14.59
-12.56%
|
16.68
+3.16%
|
16.17
|
| Salaries And Wages |
|
—
|
—
|
8.93
-4.86%
|
9.38
|
| Other Gand A |
|
16.24
+11.37%
|
14.59
-12.56%
|
16.68
+183.24%
|
5.89
|
| Total Expenses |
|
53.99
+6.11%
|
50.88
-11.49%
|
57.48
+5.00%
|
54.75
|
| Operating Income |
|
-26.52
+36.24%
|
-41.59
+20.00%
|
-51.99
+2.82%
|
-53.50
|
| Total Operating Income As Reported |
|
-26.55
+36.02%
|
-41.50
+20.42%
|
-52.15
+2.02%
|
-53.23
|
| EBITDA |
|
-22.27
+40.67%
|
-37.53
+18.51%
|
-46.05
+8.79%
|
-50.49
|
| Normalized EBITDA |
|
-22.23
+40.90%
|
-37.62
+18.03%
|
-45.90
+9.60%
|
-50.77
|
| Reconciled Depreciation |
|
3.48
+48.09%
|
2.35
-31.61%
|
3.44
+90.25%
|
1.81
|
| EBIT |
|
-25.75
+35.44%
|
-39.88
+19.42%
|
-49.49
+5.37%
|
-52.30
|
| Total Unusual Items |
|
-0.03
-133.33%
|
0.09
+159.24%
|
-0.16
-156.68%
|
0.28
|
| Total Unusual Items Excluding Goodwill |
|
-0.03
-133.33%
|
0.09
+159.24%
|
-0.16
-156.68%
|
0.28
|
| Special Income Charges |
|
-0.03
-133.33%
|
0.09
+159.24%
|
-0.16
-156.68%
|
0.28
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
-0.28
|
| Net Income |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Pretax Income |
|
-26.10
+35.83%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Net Non Operating Interest Income Expense |
|
0.45
-45.52%
|
0.83
-41.67%
|
1.42
+558.60%
|
0.21
|
| Interest Expense Non Operating |
|
0.36
-55.15%
|
0.80
-36.06%
|
1.25
+74.61%
|
0.71
|
| Net Interest Income |
|
0.45
-45.52%
|
0.83
-41.67%
|
1.42
+558.60%
|
0.21
|
| Interest Expense |
|
0.36
-55.15%
|
0.80
-36.06%
|
1.25
+74.61%
|
0.71
|
| Interest Income Non Operating |
|
0.81
-50.25%
|
1.62
-39.05%
|
2.66
+186.75%
|
0.93
|
| Interest Income |
|
0.81
-50.25%
|
1.62
-39.05%
|
2.66
+186.75%
|
0.93
|
| Other Income Expense |
|
-0.03
-133.33%
|
0.09
+159.24%
|
-0.16
-156.68%
|
0.28
|
| Tax Provision |
|
0.50
|
0.00
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.01
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Net Income From Continuing And Discontinued Operation |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Net Income Continuous Operations |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Normalized Income |
|
-26.58
+34.81%
|
-40.77
+19.39%
|
-50.58
+5.09%
|
-53.29
|
| Net Income Common Stockholders |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Diluted EPS |
|
-0.28
+61.11%
|
-0.72
+35.14%
|
-1.11
+25.50%
|
-1.49
|
| Basic EPS |
|
-0.28
+61.11%
|
-0.72
+35.14%
|
-1.11
+25.50%
|
-1.49
|
| Basic Average Shares |
|
94.73
+68.18%
|
56.33
+23.11%
|
45.75
+28.35%
|
35.65
|
| Diluted Average Shares |
|
94.73
+68.18%
|
56.33
+23.11%
|
45.75
+28.35%
|
35.65
|
| Diluted NI Availto Com Stockholders |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Gain On Sale Of PPE |
|
-0.03
-133.33%
|
0.09
+159.24%
|
-0.16
-156.68%
|
0.28
|
| Rent And Landing Fees |
|
—
|
—
|
0.72
-20.36%
|
0.90
|
| Rent Expense Supplemental |
|
—
|
—
|
0.72
-20.36%
|
0.90
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
42.21
+31.13%
|
32.19
-47.68%
|
61.53
-32.59%
|
91.28
|
| Current Assets |
|
36.98
+47.12%
|
25.14
-51.14%
|
51.45
-33.34%
|
77.19
|
| Cash Cash Equivalents And Short Term Investments |
|
27.14
+20.82%
|
22.46
-53.71%
|
48.51
-36.41%
|
76.29
|
| Cash And Cash Equivalents |
|
27.14
+20.82%
|
22.46
-53.71%
|
48.51
-6.01%
|
51.61
|
| Other Short Term Investments |
|
—
|
—
|
0.00
-100.00%
|
24.68
|
| Receivables |
|
7.45
+687.83%
|
0.94
-44.35%
|
1.70
+2878.95%
|
0.06
|
| Accounts Receivable |
|
5.55
+486.88%
|
0.94
-44.35%
|
1.70
+2878.95%
|
0.06
|
| Taxes Receivable |
|
1.90
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
1.09
+17.65%
|
0.93
+223.69%
|
0.29
|
—
|
| Other Current Assets |
|
1.31
+62.61%
|
0.81
-15.71%
|
0.95
+13.56%
|
0.84
|
| Total Non Current Assets |
|
5.23
-25.86%
|
7.05
-30.00%
|
10.08
-28.52%
|
14.10
|
| Net PPE |
|
4.32
-10.87%
|
4.84
-31.99%
|
7.12
-33.49%
|
10.70
|
| Gross PPE |
|
7.98
-6.37%
|
8.52
-20.62%
|
10.73
-28.17%
|
14.94
|
| Accumulated Depreciation |
|
-3.66
+0.46%
|
-3.68
-1.77%
|
-3.62
+14.76%
|
-4.24
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
6.32
-31.29%
|
9.20
|
| Machinery Furniture Equipment |
|
0.28
+10.89%
|
0.25
+10.71%
|
0.22
-40.58%
|
0.38
|
| Construction In Progress |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
7.58
-6.99%
|
8.15
-21.53%
|
10.39
+98.09%
|
5.25
|
| Leases |
|
0.12
+0.00%
|
0.12
+0.00%
|
0.12
+0.00%
|
0.12
|
| Non Current Prepaid Assets |
|
0.67
-65.93%
|
1.96
-27.32%
|
2.69
-13.67%
|
3.12
|
| Other Non Current Assets |
|
0.25
-3.50%
|
0.26
-4.10%
|
0.27
-3.60%
|
0.28
|
| Total Liabilities Net Minority Interest |
|
15.78
+7.41%
|
14.69
-39.90%
|
24.45
-4.52%
|
25.60
|
| Current Liabilities |
|
13.49
-1.42%
|
13.69
-19.86%
|
17.08
+47.91%
|
11.55
|
| Payables And Accrued Expenses |
|
5.46
+39.45%
|
3.92
-27.68%
|
5.42
+35.07%
|
4.01
|
| Payables |
|
4.64
+64.26%
|
2.82
-19.37%
|
3.50
+28.19%
|
2.73
|
| Accounts Payable |
|
3.95
+39.85%
|
2.82
-19.37%
|
3.50
+28.19%
|
2.73
|
| Other Payable |
|
0.69
|
—
|
—
|
—
|
| Current Accrued Expenses |
|
0.83
-24.45%
|
1.10
-42.86%
|
1.92
+49.73%
|
1.28
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.78
-56.79%
|
1.81
-18.34%
|
2.22
-2.38%
|
2.27
|
| Current Debt And Capital Lease Obligation |
|
1.91
-75.73%
|
7.87
+7.39%
|
7.33
+39.29%
|
5.26
|
| Current Debt |
|
—
|
4.33
+9.34%
|
3.96
+101.88%
|
1.96
|
| Other Current Borrowings |
|
—
|
4.33
+9.34%
|
3.96
+101.88%
|
1.96
|
| Current Capital Lease Obligation |
|
1.91
-46.02%
|
3.54
+5.11%
|
3.37
+2.06%
|
3.30
|
| Current Deferred Liabilities |
|
5.33
+6176.47%
|
0.09
-95.98%
|
2.11
|
0.00
|
| Current Deferred Revenue |
|
5.33
+6176.47%
|
0.09
-95.98%
|
2.11
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
2.29
+127.92%
|
1.00
-86.38%
|
7.36
-47.60%
|
14.05
|
| Long Term Debt And Capital Lease Obligation |
|
2.29
+127.92%
|
1.00
-86.38%
|
7.36
-47.60%
|
14.05
|
| Long Term Debt |
|
—
|
—
|
4.20
-47.70%
|
8.04
|
| Long Term Capital Lease Obligation |
|
2.29
+127.92%
|
1.00
-68.28%
|
3.16
-47.46%
|
6.02
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
26.43
+51.05%
|
17.50
-52.81%
|
37.09
-43.54%
|
65.68
|
| Common Stock Equity |
|
26.43
+51.05%
|
17.50
-52.81%
|
37.09
-43.54%
|
65.68
|
| Capital Stock |
|
0.10
+56.45%
|
0.06
+31.91%
|
0.05
+9.30%
|
0.04
|
| Common Stock |
|
0.10
+56.45%
|
0.06
+31.91%
|
0.05
+9.30%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
96.62
+56.30%
|
61.82
+30.93%
|
47.22
+9.69%
|
43.04
|
| Ordinary Shares Number |
|
96.62
+56.30%
|
61.82
+30.93%
|
47.22
+9.69%
|
43.04
|
| Additional Paid In Capital |
|
394.80
+9.88%
|
359.30
+6.23%
|
338.23
+6.97%
|
316.19
|
| Retained Earnings |
|
-368.47
-7.78%
|
-341.86
-13.50%
|
-301.19
-20.26%
|
-250.46
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
-0.10
|
| Total Equity Gross Minority Interest |
|
26.43
+51.05%
|
17.50
-52.81%
|
37.09
-43.54%
|
65.68
|
| Total Capitalization |
|
26.43
+51.05%
|
17.50
-57.62%
|
41.29
-43.99%
|
73.72
|
| Working Capital |
|
23.49
+105.16%
|
11.45
-66.69%
|
34.37
-47.63%
|
65.64
|
| Invested Capital |
|
26.43
+21.07%
|
21.83
-51.75%
|
45.25
-40.21%
|
75.68
|
| Total Debt |
|
4.20
-52.72%
|
8.88
-39.60%
|
14.70
-23.92%
|
19.32
|
| Capital Lease Obligations |
|
4.20
-7.62%
|
4.54
-30.43%
|
6.53
-29.92%
|
9.32
|
| Net Tangible Assets |
|
26.43
+51.05%
|
17.50
-52.81%
|
37.09
-43.54%
|
65.68
|
| Tangible Book Value |
|
26.43
+51.05%
|
17.50
-52.81%
|
37.09
-43.54%
|
65.68
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-21.69
+40.30%
|
-36.33
+9.09%
|
-39.96
+4.41%
|
-41.81
|
| Cash Flow From Continuing Operating Activities |
|
-21.69
+40.30%
|
-36.33
+9.09%
|
-39.96
+4.41%
|
-41.81
|
| Net Income From Continuing Operations |
|
-26.60
+34.60%
|
-40.67
+19.83%
|
-50.73
+4.30%
|
-53.01
|
| Depreciation Amortization Depletion |
|
3.48
+48.09%
|
2.35
-31.61%
|
3.44
+90.25%
|
1.81
|
| Depreciation |
|
3.48
+48.09%
|
2.35
-31.61%
|
3.44
+90.25%
|
1.81
|
| Depreciation And Amortization |
|
3.48
+48.09%
|
2.35
-31.61%
|
3.44
+90.25%
|
1.81
|
| Other Non Cash Items |
|
0.17
+0.00%
|
0.17
+0.00%
|
0.17
+221.90%
|
-0.14
|
| Stock Based Compensation |
|
4.74
-30.70%
|
6.85
-16.31%
|
8.18
-13.86%
|
9.50
|
| Operating Gains Losses |
|
0.03
+133.33%
|
-0.09
-159.24%
|
0.16
+3825.00%
|
0.00
|
| Gain Loss On Sale Of PPE |
|
0.03
+133.33%
|
-0.09
-159.24%
|
0.16
+3825.00%
|
0.00
|
| Change In Working Capital |
|
-3.29
+33.10%
|
-4.92
-427.30%
|
-0.93
-362.36%
|
0.36
|
| Change In Receivables |
|
-6.50
-963.21%
|
0.75
+145.89%
|
-1.64
-153.19%
|
3.08
|
| Changes In Account Receivables |
|
-4.60
-711.02%
|
0.75
+145.89%
|
-1.64
-153.19%
|
3.08
|
| Change In Prepaid Assets |
|
0.01
-95.88%
|
0.24
+872.00%
|
0.03
+106.93%
|
-0.36
|
| Change In Payables And Accrued Expense |
|
0.52
+127.11%
|
-1.91
-240.43%
|
1.36
+237.45%
|
-0.99
|
| Change In Accrued Expense |
|
-1.30
-5.53%
|
-1.23
-309.01%
|
0.59
+154.90%
|
-1.07
|
| Change In Payable |
|
1.81
+367.55%
|
-0.68
-188.05%
|
0.77
+827.71%
|
0.08
|
| Change In Account Payable |
|
1.12
+265.93%
|
-0.68
-188.05%
|
0.77
+827.71%
|
0.08
|
| Change In Other Working Capital |
|
5.25
+359.00%
|
-2.03
-195.98%
|
2.11
+427.44%
|
-0.65
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
0.00
|
| Change In Other Current Liabilities |
|
-2.57
-29.44%
|
-1.99
+28.73%
|
-2.79
-279.32%
|
-0.73
|
| Investing Cash Flow |
|
0.07
+134.38%
|
0.03
-99.87%
|
25.00
+201.59%
|
-24.61
|
| Cash Flow From Continuing Investing Activities |
|
0.07
+134.38%
|
0.03
-99.87%
|
25.00
+201.59%
|
-24.61
|
| Net PPE Purchase And Sale |
|
-0.14
-528.13%
|
0.03
+1500.00%
|
0.00
+101.21%
|
-0.17
|
| Purchase Of PPE |
|
-0.18
-168.18%
|
-0.07
|
0.00
+100.00%
|
-0.17
|
| Sale Of PPE |
|
0.04
-59.18%
|
0.10
+4800.00%
|
0.00
-66.67%
|
0.01
|
| Capital Expenditure |
|
-0.18
-168.18%
|
-0.07
|
—
|
-0.17
|
| Net Investment Purchase And Sale |
|
0.21
|
0.00
-100.00%
|
25.00
+202.27%
|
-24.45
|
| Purchase Of Investment |
|
-16.29
|
0.00
|
0.00
+100.00%
|
-29.45
|
| Sale Of Investment |
|
16.50
|
0.00
-100.00%
|
25.00
+400.00%
|
5.00
|
| Financing Cash Flow |
|
26.29
+156.67%
|
10.24
-13.63%
|
11.86
-77.90%
|
53.66
|
| Cash Flow From Continuing Financing Activities |
|
26.29
+156.67%
|
10.24
-13.63%
|
11.86
-77.90%
|
53.66
|
| Net Issuance Payments Of Debt |
|
-4.50
-12.53%
|
-4.00
-99.95%
|
-2.00
-120.00%
|
10.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
10.00
|
| Repayment Of Debt |
|
-4.50
-12.53%
|
-4.00
-99.95%
|
-2.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
10.00
|
| Long Term Debt Payments |
|
-4.50
-12.53%
|
-4.00
-99.95%
|
-2.00
|
0.00
|
| Net Long Term Debt Issuance |
|
-4.50
-12.53%
|
-4.00
-99.95%
|
-2.00
-120.00%
|
10.00
|
| Net Common Stock Issuance |
|
30.79
+116.47%
|
14.22
+6.25%
|
13.39
-65.94%
|
39.30
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.02
-96.19%
|
0.47
-89.94%
|
4.70
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.34
|
| Changes In Cash |
|
4.68
+117.96%
|
-26.05
-740.72%
|
-3.10
+75.71%
|
-12.76
|
| Beginning Cash Position |
|
22.61
-53.54%
|
48.66
-5.99%
|
51.76
-19.77%
|
64.52
|
| End Cash Position |
|
27.29
+20.69%
|
22.61
-53.54%
|
48.66
-5.99%
|
51.76
|
| Free Cash Flow |
|
-21.86
+39.93%
|
-36.40
+8.92%
|
-39.96
+4.80%
|
-41.98
|
| Interest Paid Supplemental Data |
|
0.21
-68.01%
|
0.67
-33.30%
|
1.00
+75.96%
|
0.57
|
| Amortization Of Securities |
|
-0.21
|
0.00
+100.00%
|
-0.23
+27.10%
|
-0.32
|
| Common Stock Issuance |
|
30.79
+116.47%
|
14.22
+6.25%
|
13.39
-65.94%
|
39.30
|
| Issuance Of Capital Stock |
|
30.79
+116.47%
|
14.22
+6.25%
|
13.39
-65.94%
|
39.30
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-22 View
- 8-K2026-04-13 View
- 42026-04-10 View
- 42026-04-10 View
- 42026-04-10 View
- 8-K2026-04-07 View
- 8-K2026-03-27 View
- 8-K2026-03-16 View
- 10-K2026-03-16 View
- 8-K2026-02-18 View
- 8-K2026-02-12 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-02 View
- 8-K2025-12-19 View
- 42025-12-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|